Select therapeutic use:
Indications for LAMISIL TABLETS:
Onychomycosis of the toenail or fingernail due to tinea unguium.
250mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).
Chronic or active liver disease.
Onychomycosis: confirm diagnosis with nail specimen. Pre-existing hepatic disease or renal impairment (CrCl <50mL/min): not recommended. Perform LFTs prior to and periodically during treatment. Discontinue if hepatic injury, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), taste/smell disturbances, severe neutropenia (neutrophils ≤1000 cells/mm3), thrombotic microangiopathy occurs, or if lupus erythematosus is suspected. Monitor CBCs if immunodeficient. Pregnancy (Cat.B), nursing mothers: not recommended.
Potentiated by cimetidine. Antagonized by rifampin. May potentiate drugs metabolized by CYP2D6 (eg, tricyclic antidepressants, SSRIs, beta-blockers). May be potentiated by CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). Potentiates caffeine. Antagonizes cyclosporine.
Headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbances, nausea, abdominal pain, flatulence, urticaria; also children: nasopharyngitis, pyrexia, cough, upper respiratory infection; rare: hepatotoxicity, depressive symptoms, smell disturbances.
Tabs—30, 100; Packets—14, 42